Inhaled Formulations of Large Dosage Seretide on Severe Chronic Obstructive Pulmonary Disease_West China Medical Journal

Authors：

ZHANG Rong , DAI Guangming

Department of Respiratory, The First Hospital of Suining, Suining, Sichuan 629000, P.R.China;

Corresponding?author：

Keywords：

沙美特羅替卡松; 慢性阻塞性肺疾病; 穩定期

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】目的 觀察沙美特羅替卡松粉吸入劑（沙美特羅50 μg/氟替卡松500 μg）治療穩定期Ⅲ~Ⅳ級慢性阻塞性肺疾病（COPD）的療效及安全性。方法將2008年1-12月就診的62例穩定期Ⅲ~Ⅳ級COPD患者隨機分成對照組和治療組。對照組采用常規傳統治療方法，口服茶堿緩釋片、祛痰劑；治療組在常規傳統治療的基礎上，加用沙美特羅替卡松粉吸入劑。6個月后評估兩組患者肺功能、血氣分析、呼吸困難程度及不良反應。治療過程中，兩組各有2例患者因失訪退出研究。結果治療前，對照組、治療組1 s用力呼氣量（FEV1）和FEV1%預計值比較，無統計學意義（P gt;0.05）；治療后，治療組FEV1和FEV1%預計值明顯增加，有統計學意義（P lt;0.05）。對照組治療前后比較無改變（P gt;0.05），治療組較對照組呼吸困難程度明顯好轉，臨床癥狀評分明顯下降，兩組間差異有統計學意義（P lt;0.05）。治療結束時兩組上述各指標比較，差異有統計學意義（P lt;0.05）。兩組均有少數出現咽喉不適，患者耐受好。結論沙美特羅替卡松粉吸入劑治療穩定期Ⅲ~Ⅳ級COPD患者有效。
【Abstract】 Objective To observe the efficacy and safety of inhaled formulations of Seretide (salmeterol 50 μg / fluticasone 500 μg) on grade Ⅲ ~ Ⅳ stable chronic obstructive pulmonary disease (COPD). Methods Sixty-two patients of grade Ⅲ-Ⅳ stable COPD were randomly divided into control group and treatment group. The control group was treated by conventional methods, oral theophylline and expectorant agents,while the treatment group was treated by inhalation of large dosage Seretide be added in the conventional treatment based on traditional. After six months, the lung function, blood gas analysis, respiratory difficulty and adverse effects were assessed. Results Before the treatment, the differences of forced expiratory volume in one second (FEV1) and FEV1% predicted value in the two groups were not statistically significant (P gt;0.05). After treatment, FEV1 and FEV1% predicted value of treatment group were increased significantly(P lt;0.05). The control group showed no significant change before and after treatment(P gt;0.05). The respiratory difficulty imprvoved significantly,while clinical symptom score decreased significantly in the treatment group,which compared with the control group (P lt;0.05). A few appeared thoat discomfort in the two groups. Well tolerated in patients. Conclusion Inhaled formulations of Seretide was effective and safty on stable period COPD patients with grade Ⅲ-Ⅳ.

Citation： ZHANG Rong,DAI Guangming. Inhaled Formulations of Large Dosage Seretide on Severe Chronic Obstructive Pulmonary Disease. West China Medical Journal, 2010, 25(8): 1409-1411. doi: Copy

1.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南（2007年修訂版）[J]. 中華結核和呼吸雜志, 2007, 30(1): 8-17. .
2.	Calverley P, Pauwels R, Vestboet J, et al. Combined salmeterol and uticasone in the treatment of chronic obstructive pulmonary disease: arandomised controlled trial[J]. Lancet, 2003, 361: 449-456. .
3.	O’Donnell R, Breen D, Wilson S, et al. In ammatory cells in the airways in COPD[J]. Thotax, 2006, 61: 448-454. .
4.	Cosio MG, Saetta AA. Immunologic aspects of chronic obstructive pulmonary disease[J]. N Engl J Med, 2009, 360: 2445-2454. .
5.	俞森洋. 腎上腺皮質激素在呼吸系疾病的應用. 現代呼吸治療學[M]. 北京: 科學技術文獻出版社, 2003: 1258-1262. .
6.	何樺, 鄭勁平. 吸入型糖皮質激素和吸入型長效β2受體激動劑在COPD中的聯合應用[J]. 國外醫學?呼吸系統分冊, 2005, 25(3): 194-196.

1. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南（2007年修訂版）[J]. 中華結核和呼吸雜志, 2007, 30(1): 8-17. .
2. Calverley P, Pauwels R, Vestboet J, et al. Combined salmeterol and uticasone in the treatment of chronic obstructive pulmonary disease: arandomised controlled trial[J]. Lancet, 2003, 361: 449-456. .
3. O’Donnell R, Breen D, Wilson S, et al. In ammatory cells in the airways in COPD[J]. Thotax, 2006, 61: 448-454. .
4. Cosio MG, Saetta AA. Immunologic aspects of chronic obstructive pulmonary disease[J]. N Engl J Med, 2009, 360: 2445-2454. .
5. 俞森洋. 腎上腺皮質激素在呼吸系疾病的應用. 現代呼吸治療學[M]. 北京: 科學技術文獻出版社, 2003: 1258-1262. .
6. 何樺, 鄭勁平. 吸入型糖皮質激素和吸入型長效β2受體激動劑在COPD中的聯合應用[J]. 國外醫學?呼吸系統分冊, 2005, 25(3): 194-196.

West China Medical Journal

Inhaled Formulations of Large Dosage Seretide on Severe Chronic Obstructive Pulmonary Disease

Abstract Full text Figures/Tables Video References Cited by

Format

Content